Compare Hinge Health Inc. Class A Common Stock (HNGE) vs Invesco S&P 500 Momentum ETF (SPMO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hinge Health Inc. Class A Common Stock vs Invesco S&P 500 Momentum ETF — how do they compare? Hinge Health Inc. Class A Common Stock trades at $104.95 (market cap $8.48B), while Invesco S&P 500 Momentum ETF trades at $144.03 (market cap $23.04B). The key difference: Invesco S&P 500 Momentum ETF is far larger — about 2.7× Hinge Health Inc. Class A Common Stock's market cap, and Hinge Health Inc. Class A Common Stock is trading nearer its 52-week high, Invesco S&P 500 Momentum ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Hinge Health Inc. Class A Common Stock for 0 Days and Invesco S&P 500 Momentum ETF for 55 Days on average.
| HNGE | SPMO | |
|---|---|---|
Market Cap | $8.48B | $23.04B |
Volume | 879,799 | 2,008,654 |
Sector | Health | Broad Market / Factor |
52-Week High | $105.14 | $161.66 |
52-Week Low | $31.17 | $107.84 |
Typical Hold Time | 0 Days | 55 Days |
Enterprise Value | $8.10B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hinge Health (HNGE) trades at $105.14, up 0.31% on the day and near its 52-week high. The stock shows strong analyst support with a 93.75% buy rating, though the current price exceeds the consensus target of $101.62. Recent earnings beat expectations in two of the last three quarters, with Q3 2026 results due November 2. Fundamentals indicate robust revenue growth projections from $588 million in 2025 to $720 million in 2026, alongside a shift to profitability, but valuation multiples like EV/EBITDA at 82.33 remain elevated.
The outlook is cautiously optimistic given projected profitability and expansion into migraine and GI care, but risks include high insider selling, competitive pressures, and the stock's premium valuation. Execution on growth targets and Q3 earnings will be critical for sustaining momentum.
SPMO, the Invesco S&P 500 Momentum ETF, trades at $148.03, down 0.89% on the day amid a bearish technical signal. The ETF recently completed its semi-annual reconstitution, adding 54 stocks including Apple and Merck while removing Nvidia. Its momentum strategy has historically outperformed the S&P 500 but faces near-term volatility from concentrated sector exposure.
Outlook remains mixed with strong long-term momentum performance offset by current technical weakness. Investment opportunity lies in capturing S&P 500's fastest-rising stocks, though risks include high volatility and sector concentration. The ETF's structural edge suggests potential for continued outperformance despite recent underperformance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Hinge Health Inc. Class A Common Stock
Hinge Health Inc. operates a digital musculoskeletal (MSK) care platform that delivers exercise therapy for joint and muscle conditions through health plans and employers. Its Precision Motion Technology combines wearable sensors and computer vision to guide patients through clinician-directed physical therapy remotely.
Read more on HNGE →About Invesco S&P 500 Momentum ETF
SPMO is designed to track the investment results of the S&P 500 Momentum Index. This index measures the performance of stocks in the S&P 500 that exhibit the highest momentum, or the greatest price appreciation, over the trailing 12 months, while excluding the most recent month. By investing in these high-momentum stocks, SPMO seeks to capitalize on the historical trend that stocks with strong recent performance tend to continue that performance in the near term, offering a systematic approach to factor investing within the large-cap U.S. equity market.
Read more on SPMO →
